Evidence map›Paper›PMID 35736452›Full record

ArticleMetabolites2022

Quantitative Comparison of Statistical Methods for Analyzing Human Metabolomics Data.

Mir Henglin, Brian L Claggett, Joseph Antonelli, Mona Alotaibi, Gino Alberto Magalang, Jeramie D Watrous, Kim A Lagerborg, Gavin Ovsak, Gabriel Musso, Olga V Demler and 4 more

Abstract read
In one paragraph

Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Application of Metabolomics across the Spectrum of Pulmonary and Critical Care Medicine.American journal of respiratory cell and molecular biology · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Sex-related Differences in Eicosanoid Levels in Chronic Thromboembolic Pulmonary Hypertension.American journal of respiratory cell and molecular biology · 2023
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mir HenglinCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Brian L ClaggettCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Joseph AntonelliCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Mona AlotaibiDepartments of Medicine & Pharmacology, University of California San Diego, La Jolla, CA 92161, USA.
Gino Alberto MagalangSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Jeramie D WatrousDepartments of Medicine & Pharmacology, University of California San Diego, La Jolla, CA 92161, USA.
Kim A LagerborgDepartments of Medicine & Pharmacology, University of California San Diego, La Jolla, CA 92161, USA.
Gavin OvsakCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Gabriel MussoCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-8778-8248
Olga V DemlerPreventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Ramachandran S VasanPreventive Medicine, Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA.
Martin G LarsonFramingham Heart Study, Framingham, MA 01702, USA.ORCID 0000-0002-9631-1254
Mohit JainDepartments of Medicine & Pharmacology, University of California San Diego, La Jolla, CA 92161, USA.
Susan ChengCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Funding

GRADUATE TRAINING IN BIOSTATISTICST32ES007142 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI Brent Andrew Coull · 1985 to 2026
$11.9M
The Microvascular Aging and Eicosanoids - Women's Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (SCORE)U54AG065141 · NIA · CEDARS-SINAI MEDICAL CENTER · PI BAIREY MERZ, CATHLEEN NOEL · 2020 to 2024
$8.7M
Cardiac microstructure and the immune-inflammatory response to SARS-CoV-2R01HL131532 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN, LI, DEBIAO · 2016 to 2025
$6.6M
Inflammatory mediators of cardiometabolic risk in LatinosR01HL147853 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AVERY, CHRISTY LEIGH · 2020 to 2023
$3.8M
Mapping the Plasma Exposome and its Association with Human Cardiovascular DiseaseR01ES027595 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAIN, MOHIT · 2017 to 2021
$3.3M
Mediators of Systemic Inflammation and Heart Failure Risk in the CommunityR01HL143227 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2019 to 2022
$3.3M
Vaccine Induced Immune-Inflammatory Response and Cardiovascular RiskR01HL151828 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2021 to 2024
$3.0M
Reducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid PathwaysR01HL134811 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MORA, SAMIA · 2017 to 2020
$3.0M
Inflammatory Mediators, Cardiovascular Health, and Longevity in WomenR01HL134168 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2016 to 2019
$1.6M
CHD Risk and Metabolomic Profiles of Discordant LipidsK01HL135342 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DEMLER, OLGA · 2017 to 2021
$857k
THE FRAMINGHAM HEART STUDY-N01HC25195-268025195-268025195N01HC025195 · HC · TRUSTEES OF BOSTON UNIVERSITY · PI WOLF, PHILIP A · 2002 to 2006
–
American Heart Association CVGPS Pathway AwardDoris Duke Charitable Foundation 2015092Frontiers of Innovation Scholars Program N/ANHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INHLBI NIH HHS K01 HL135342NHLBI NIH HHS N01 HC025195NHLBI NIH HHS R01 HL131532NHLBI NIH HHS R01 HL134168NHLBI NIH HHS R01 HL134811NHLBI NIH HHS R01 HL143227NHLBI NIH HHS R01 HL147853NHLBI NIH HHS R01 HL151828NIA NIH HHS U54 AG065141NIEHS NIH HHS R01 ES027595NIEHS NIH HHS T32 ES007142NIH HHS HHSN268201500001INIH HHS K01-HL135342NIH HHS N01-HC-25195NIH HHS R01-ES027595NIH HHS R01-HL134168NIH HHS R01-HL134811NIH HHS T32-ES007142Tobacco Related Disease Research Program N/A
6 · The paper itself

Abstract

Emerging technologies now allow for mass spectrometry-based profiling of thousands of small molecule metabolites ('metabolomics') in an increasing number of biosamples. While offering great promise for insight into the pathogenesis of human disease, standard approaches have not yet been established for statistically analyzing increasingly complex, high-dimensional human metabolomics data in relation to clinical phenotypes, including disease outcomes. To determine optimal approaches for analysis, we formally compare traditional and newer statistical learning methods across a range of metabolomics dataset types. In simulated and experimental metabolomics data derived from large population-based human cohorts, we observe that with an increasing number of study subjects, univariate compared to multivariate methods result in an apparently higher false discovery rate as represented by substantial correlation between metabolites directly associated with the outcome and metabolites not associated with the outcome. Although the higher frequency of such associations would not be considered false in the strict statistical sense, it may be considered biologically less informative. In scenarios wherein the number of assayed metabolites increases, as in measures of nontargeted versus targeted metabolomics, multivariate methods performed especially favorably across a range of statistical operating characteristics. In nontargeted metabolomics datasets that included thousands of metabolite measures, sparse multivariate models demonstrated greater selectivity and lower potential for spurious relationships. When the number of metabolites was similar to or exceeded the number of study subjects, as is common with nontargeted metabolomics analysis of relatively small cohorts, sparse multivariate models exhibited the most-robust statistical power with more consistent results. These findings have important implications for metabolomics analysis in human disease.

Indexed as

metabolomicsmultivariatestatistical methodsunivariate

Identifiers

PMID35736452
PMCPMC9227835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.